Monopar Therapeutics (MNPR) Equity Ratio (2016 - 2025)

Monopar Therapeutics has disclosed Equity Ratio across 10 years of filings, most recently posting 0.98 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.98, up 7.3% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.98 (up 7.3% YoY), and the FY2025 annual result was 0.98, up 7.3% from the prior year.
• Equity Ratio came in at 0.98 for Q4 2025 at Monopar Therapeutics, roughly flat from 0.98 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q3 2025 to a low of 0.76 in Q1 2023.
• The 5-year median for Equity Ratio is 0.89 (2022), against an average of 0.88.
• Across the five-year window, Equity Ratio decreased 19.51% in 2023 and gained 20.45% in 2025, its largest moves.
• Monopar Therapeutics' Equity Ratio stood at 0.92 in 2021, then dropped by 17.35% to 0.76 in 2022, then dropped by 0.27% to 0.76 in 2023, then gained by 19.99% to 0.91 in 2024, then rose by 7.3% to 0.98 in 2025.
• The last three Equity Ratio figures came in at 0.98 (Q4 2025), 0.98 (Q3 2025), and 0.97 (Q2 2025), per Business Quant data.